<DOC>
	<DOCNO>NCT00647738</DOCNO>
	<brief_summary>The objective study investigate bioequivalence Genpharm 's baclofen tablet follow single , oral 20 mg ( 1 x 20 mg ) dose compare Baclofen USP ( Watson Laboratories Inc. , USA ) administer fasting condition . Twenty-seven ( 27 ) healthy , light- , non- ex-smoking subject least 18 year age randomize , two-period , two-treatment crossover bioequivalence study conduct Eric Sicard , M.D . Algorithme Pharma Inc. Montreal , Canada . Statistical analysis data reveals 90 % confidence interval within acceptable bioequivalent range 80 % 125 % natural log transform parameter AUCT , AUCI Cmax . This study demonstrate Genpharm 's baclofen 20 mg tablet bioequivalent Baclofen USP 20 mg tablet ( Watson Laboratories Inc. , USA ) administer fasting condition .</brief_summary>
	<brief_title>Comparative Bioavailability Study Baclofen 20 mg Tablets Healthy Male Volunteers / Fasting State</brief_title>
	<detailed_description />
	<criteria>Subjects meet follow criterion may include study : Availability subject entire study period willingness adhere protocol requirement evidence informed consent form duly sign subject Males age 18 55 year body mass index ( BMI ) great equal 19 30 ; demographic data ( sex , age , ethnic group , body weight , height smoke habit ) record report final report Clinical laboratory value within laboratory 's state normal range ; within range , must without clinical significance must record CRF ( laboratory test present section 7.1.3 ) Healthy accord laboratory result physical examination Normal cardiovascular function accord ECG Subjects light , non exsmokers Significant history hypersensitivity baclofen relate product well severe hypersensitivity reaction ( like angioedema ) drug Presence history significant gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism excretion drug know potentiate predispose undesired effect Presence history significant cardiovascular , pulmonary , hematologic , neurologic , psychiatric , endocrine , immunologic dermatologic disease Presence history urologic disease Presence history neuromuscular disease Maintenance therapy drug , significant history drug dependency , alcohol abuse ( &gt; 3 unit alcohol per day , intake excessive alcohol , acute chronic ) , serious psychological disease Any clinically significant illness previous 28 day day 1 study Use enzymemodifying drug previous 28 day day 1 study ( barbiturate , corticosteroid , phenylhydantoins , etc . ) Participation another clinical trial previous 28 day day 1 study Donation 500 mL blood ( Canadian Blood Services , HemaQuebec , clinical study , etc . ) previous 56 day day 1 study Positive urine screen drug abuse ( drug names present section 7.1.4 ) Positive result HIV , HBsAg antiHCV test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>